Steven C. Jones Sells 203,500 Shares of NeoGenomics, Inc. (NEO) Stock

NeoGenomics, Inc. (NASDAQ:NEO) insider Steven C. Jones sold 203,500 shares of NeoGenomics stock in a transaction on Wednesday, August 1st. The stock was sold at an average price of $14.00, for a total transaction of $2,849,000.00. Following the completion of the transaction, the insider now directly owns 241,815 shares in the company, valued at $3,385,410. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Shares of NASDAQ:NEO traded down $0.01 on Wednesday, hitting $13.99. 413,900 shares of the company were exchanged, compared to its average volume of 430,945. NeoGenomics, Inc. has a 1-year low of $7.08 and a 1-year high of $14.61. The company has a current ratio of 2.03, a quick ratio of 1.85 and a debt-to-equity ratio of 0.53. The company has a market capitalization of $1.11 billion, a P/E ratio of 233.17, a PEG ratio of 7.66 and a beta of 0.52.

Get NeoGenomics alerts:

NeoGenomics (NASDAQ:NEO) last posted its quarterly earnings data on Tuesday, July 24th. The medical research company reported $0.05 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.04 by $0.01. NeoGenomics had a negative net margin of 0.98% and a negative return on equity of 0.36%. The business had revenue of $67.70 million during the quarter, compared to the consensus estimate of $66.40 million. During the same period in the previous year, the firm posted $0.04 earnings per share. The business’s revenue for the quarter was up 8.7% compared to the same quarter last year. equities analysts forecast that NeoGenomics, Inc. will post 0.09 EPS for the current year.

Several large investors have recently bought and sold shares of NEO. Quantitative Systematic Strategies LLC acquired a new stake in shares of NeoGenomics during the first quarter worth $100,000. Campbell & CO Investment Adviser LLC lifted its stake in shares of NeoGenomics by 64.3% during the first quarter. Campbell & CO Investment Adviser LLC now owns 17,127 shares of the medical research company’s stock worth $140,000 after buying an additional 6,700 shares during the period. OMERS ADMINISTRATION Corp acquired a new stake in shares of NeoGenomics during the first quarter worth $152,000. Wrapmanager Inc. lifted its stake in shares of NeoGenomics by 36.6% during the first quarter. Wrapmanager Inc. now owns 26,857 shares of the medical research company’s stock worth $219,000 after buying an additional 7,192 shares during the period. Finally, MetLife Investment Advisors LLC acquired a new stake in shares of NeoGenomics during the fourth quarter worth $235,000. Institutional investors and hedge funds own 83.09% of the company’s stock.

NEO has been the topic of several analyst reports. BTIG Research raised shares of NeoGenomics from a “neutral” rating to an “outperform” rating in a report on Monday, April 16th. Zacks Investment Research lowered shares of NeoGenomics from a “hold” rating to a “sell” rating in a report on Thursday, July 19th. BidaskClub raised shares of NeoGenomics from a “hold” rating to a “buy” rating in a report on Wednesday, April 18th. ValuEngine raised shares of NeoGenomics from a “hold” rating to a “buy” rating in a report on Tuesday, April 17th. Finally, First Analysis downgraded shares of NeoGenomics from an “overweight” rating to an “equal weight” rating and set a $11.00 price objective for the company. in a research note on Wednesday, May 2nd. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company. NeoGenomics has a consensus rating of “Buy” and an average price target of $17.50.

About NeoGenomics

NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States. It operates through Clinical Services and Pharma Services segments. The company laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, and other clinical laboratories.

Featured Article: Diversification Important in Investing

Insider Buying and Selling by Quarter for NeoGenomics (NASDAQ:NEO)

Leave a Reply

Your email address will not be published. Required fields are marked *